SAN FRANCISCO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that data from its VIR-2218 clinical program will be featured at the European Association for the Study of the Liver (EASL) Digital International Liver Congress from August 27-29, 2020. VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi) for the potential treatment of chronic hepatitis B virus (HBV) infection and is the first investigational medicine from Virs partnership with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
Among the accepted abstracts is an oral presentation of preliminary antiviral activity and safety results from an ongoing Phase 2 study of VIR-2218 in patients with chronic HBV on nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), which are standard of care. The data demonstrate that two monthly doses of VIR-2218 resulted in substantial, dose-dependent and durable reductions in hepatitis B surface antigen (HBsAg), a marker of active hepatitis B infection. The data also suggests that the Enhanced Stabilization Chemistry-Plus (ESC+) incorporated into VIR-2218 may result in an improved hepatic safety profile. Additional abstracts include safety and pharmacokinetic data from a Phase 1 study of VIR-2218, as well as preclinical data.
Chronic HBV infection is a major public health condition impacting almost 300 million people worldwide, and innovative approaches that do not require lifelong treatment are needed to sustainably address the disease, said Phillip Pang, M.D., Ph.D., Chief Medical Officer of Vir. By suppressing HBV protein expression, VIR-2218 is not only a potent antiviral, but also may serve to remove antigenic inhibition of T and B cell activity directed against HBV, enabling immunologic control. The well-tolerated and substantial dose-dependent reduction in HBsAg demonstrated to date by VIR-2218 supports our belief that it has the potential to serve as the backbone of a finite treatment regimen aimed at providing a functional cure for HBV.
VIR-2218 Scientific Research Presented at EASL
Oral Presentation:
The following poster presentations will be available on demand:
Advancing Clinical Trials for HBV Therapies
Based on preliminary Phase 2 results, Vir initiated a Phase 2 trial of VIR-2218 administered in combination with pegylated interferon alpha-2a, an approved immunomodulatory agent. Initial clinical data are expected next year.
In May 2020, Vir initiated a Phase 1 clinical trial of VIR-3434, an HBV-neutralizing monoclonal antibody with the potential to also be a therapeutic T cell vaccine. Recently, the first chronic HBV patient was treated in the program, following the study design to progress from healthy volunteers to HBV patients in a staggered, parallel fashion.
A Phase 2 clinical trial of VIR-2218 in combination with VIR-3434 is expected in 2021.
About Hepatitis BApproximately 290million people globally are chronically infected with HBV and approximately 900,000 of them die from HBV-associated complications each year. There is a significant unmet medical need for more effective therapies that lead to life-long control of the virus after a finite duration of therapy, which is the definition of a functional cure. For a registrational trial to demonstrate a functional cure, the formal endpoint accepted by theU.S. Food and Drug Administration(FDA) is undetectable hepatitis B virus surface antigen (HBsAg), defined as less than 0.05 international units per milliliter, as well as HBV DNA less than the lower limit of quantification, in the blood six months after the end of therapy. Currently, a year-long course of pegylated interferon-alpha (PEG-IFN-) is the best available curative therapy. It has a low functional cure rate of approximately three to seven percent. Alternatively, suppressive therapy with nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) is commonly used, but patients often require a lifetime of therapy.
About VIR-2218VIR-2218 is a subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the companys collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
About VIR-3434VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and also to reduce the level of virions and subviral particles in the blood. VIR-3434 has been engineered to have an extended half-life as well as to potentially function as a T cell vaccine against HBV in infected patients.
About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. For more information, please visitwww.vir.bio.
Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, potential, aim, believe and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Virs expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-2218, pegylated interferon-alpha, ESC+ technology and VIR-3434 (individually or in combination), the expected timing of commencement of clinical trials and availability of clinical data, our goals with respect to the prophylaxis and/or treatment of HBV, the criteria for a functional cure of HBV and the potential ability of our product candidates to demonstrate such criteria, the potential of ESC+ technology to enhance the safety and therapeutic index of VIR-2218 and other siRNAs, and the potential benefits of Virs collaboration with Alnylam Pharmaceuticals, Inc. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials, difficulties in obtaining regulatory approval, challenges in accessing manufacturing capacity, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, delays in or disruptions to Virs business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Virs filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
- Angel Biotechnology (ABH) - Video [Last Updated On: November 28th, 2011] [Originally Added On: November 28th, 2011]
- Curing the entire world through biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnological innovation on Farming Skill [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Growth and development of Biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnology: Boon to Human being [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Philippines banks on biotechnology to deal with enviromentally friendly issues, food security considerations [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Philippines banks on biotechnology to deal with enviromentally friendly issues, food security considerations [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnology: Boon to Human being [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Growth and development of Biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Biotechnological innovation on Farming Skill [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Curing the entire world through biotechnology [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- Scientists make ethical stem cells from skin of a rat [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- India emerging as a global hub for stem cell research [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- India emerging as a global hub for stem cell research [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- Scientists make ethical stem cells from skin of a rat [Last Updated On: January 22nd, 2012] [Originally Added On: January 22nd, 2012]
- Alzheimer Disease - New Drugs, Markets and Companies [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Amazing Stem Cell Therapy Results | Before [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Stemcell therapy for pets - Mi Mascota - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Stem cells for dogs? New pain management therapy works for pets - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Riot's Lameness Moving Exam Pre Stem Cell Therapy - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Riot's Lameness Palpation Exam Pre Stem Cell Therapy - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Ariel's Stem Cell Miracle! - Video [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- South Korea again gives a go ahead to use of human eggs in cloning research [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- South Korea again gives a go ahead to use of human eggs in cloning research [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- Angel Biotechnology - Contracts with Materia Medica [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Cellerant Therapeutics Appoints Lowell E. Sears to Board of Directors [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Angel Biotechnology - Grant of Share Options [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- RBCC Closes Deal with Game Changing Biotech Firm [Last Updated On: March 16th, 2012] [Originally Added On: March 16th, 2012]
- The year of the dragon looks auspicious for Australian Biotechnology [Last Updated On: March 25th, 2012] [Originally Added On: March 25th, 2012]
- The year of the dragon looks auspicious for Australian Biotechnology [Last Updated On: March 25th, 2012] [Originally Added On: March 25th, 2012]
- David Allan Lauded for Leadership – Biotechnology Leader Named to Industry Award [Last Updated On: May 9th, 2012] [Originally Added On: May 9th, 2012]
- Angel Biotechnology - Angel signs new contract with ReNeuron [Last Updated On: May 17th, 2012] [Originally Added On: May 17th, 2012]
- MYOS Names Veteran Biotechnology Executive Dr. Sol J. Barer to Chair Scientific Advisory Board [Last Updated On: June 27th, 2012] [Originally Added On: June 27th, 2012]
- StemCells and Keryx Biopharmaceuticals Showing Strong Gains as Biotechnology Industry Soars in 2012 [Last Updated On: July 24th, 2012] [Originally Added On: July 24th, 2012]
- Osiris Therapeutics and Pluristem Therapeutics Showing Impressive Growth as Biotech Industry Thrives in 2012 [Last Updated On: August 4th, 2012] [Originally Added On: August 4th, 2012]
- Allele Biotechnology Announces New Advance in Production of Human Stem Cells [Last Updated On: September 14th, 2012] [Originally Added On: September 14th, 2012]
- BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum [Last Updated On: September 25th, 2012] [Originally Added On: September 25th, 2012]
- Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act [Last Updated On: October 2nd, 2012] [Originally Added On: October 2nd, 2012]
- Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures [Last Updated On: October 15th, 2012] [Originally Added On: October 15th, 2012]
- David Lichtenstein: Biotechnology is Rich Area for Investment [Last Updated On: November 2nd, 2012] [Originally Added On: November 2nd, 2012]
- Donna Dickenson introduces Bioethics - Video [Last Updated On: November 2nd, 2012] [Originally Added On: November 2nd, 2012]
- Coare Biotechnology and ChemDiv Establish Co-Marketing and Service Collaboration [Last Updated On: November 9th, 2012] [Originally Added On: November 9th, 2012]
- blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health - Video [Last Updated On: November 12th, 2012] [Originally Added On: November 12th, 2012]
- Research and Markets: Research Report on the Biotechnology Market in India 2012 [Last Updated On: November 18th, 2012] [Originally Added On: November 18th, 2012]
- Life Un(Ltd), Charis Thompson, Three Times a Woman- A Gendered Economy of Stem Cell Innovation Pt. 2 - Video [Last Updated On: November 30th, 2012] [Originally Added On: November 30th, 2012]
- Life UnLtd, Charis Thompson, Three Times a Woman A Gendered Economy of Stem Cell Innovation Pt 1 - Video [Last Updated On: November 30th, 2012] [Originally Added On: November 30th, 2012]
- Biotechnology: Things you should know about Gene Therapy [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- Biotechnology: Things you should know about Gene Therapy [Last Updated On: December 2nd, 2012] [Originally Added On: December 2nd, 2012]
- Top trends for Biotechnology [Last Updated On: December 9th, 2012] [Originally Added On: December 9th, 2012]
- Top trends for Biotechnology [Last Updated On: December 9th, 2012] [Originally Added On: December 9th, 2012]
- Angel Biotechnology losses widen [Last Updated On: December 10th, 2012] [Originally Added On: December 10th, 2012]
- Why Biotech ETFs are a Top Sector in 2012 [Last Updated On: December 19th, 2012] [Originally Added On: December 19th, 2012]
- Things to know about the real fountain of youth [Last Updated On: January 11th, 2013] [Originally Added On: January 11th, 2013]
- Things to know about the real fountain of youth [Last Updated On: January 20th, 2013] [Originally Added On: January 20th, 2013]
- DNA testing is Good or Bad: Let’s Discuss [Last Updated On: March 2nd, 2013] [Originally Added On: March 2nd, 2013]
- Computer Review Announces New Tools to Deal with the Flood of Information from the Biotechnology Sector [Last Updated On: March 7th, 2013] [Originally Added On: March 7th, 2013]
- DNA testing is Good or Bad: Let’s Discuss [Last Updated On: March 10th, 2013] [Originally Added On: March 10th, 2013]
- The Mystery about Cyanide Taste [Last Updated On: March 31st, 2013] [Originally Added On: March 31st, 2013]
- The Mystery about Cyanide Taste [Last Updated On: April 14th, 2013] [Originally Added On: April 14th, 2013]
- Are Biodegradable Heart Stents Safe? [Last Updated On: April 17th, 2013] [Originally Added On: April 17th, 2013]
- Piper Jaffray Biotechnology Analyst Participates in Historical Medical Event at the Vatican [Last Updated On: April 17th, 2013] [Originally Added On: April 17th, 2013]
- Are Biodegradable Heart Stents Safe? [Last Updated On: April 21st, 2013] [Originally Added On: April 21st, 2013]
- TaiGen Biotechnology Announces Submission of New Drug Application for Nemonoxacin in Taiwan and Mainland China [Last Updated On: May 17th, 2013] [Originally Added On: May 17th, 2013]
- How good to use home pregnancy tests [Last Updated On: June 1st, 2013] [Originally Added On: June 1st, 2013]
- How good to use home pregnancy tests [Last Updated On: June 2nd, 2013] [Originally Added On: June 2nd, 2013]
- Questions you should ask to doctor for Alzheimer disease [Last Updated On: July 6th, 2013] [Originally Added On: July 6th, 2013]
- Questions you should ask to doctor for Alzheimer disease [Last Updated On: July 7th, 2013] [Originally Added On: July 7th, 2013]
- BetaStem Therapeutics Retains Conditas Biotechnology Group for Business Development and Corporate Strategy [Last Updated On: July 18th, 2013] [Originally Added On: July 18th, 2013]
- Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology [Last Updated On: August 8th, 2013] [Originally Added On: August 8th, 2013]
- Matric Revision: Life Sciences: Genetics: Biotechnology (5/9): Cloning (1/4) - Video [Last Updated On: October 27th, 2013] [Originally Added On: October 27th, 2013]
- Matric Revision: Life Sciences: Genetics: Biotechnology (6/9): Cloning (2/4) - Video [Last Updated On: October 29th, 2013] [Originally Added On: October 29th, 2013]
- History of biotechnology - Wikipedia, the free encyclopedia [Last Updated On: December 16th, 2013] [Originally Added On: December 16th, 2013]
- Exciting business ideas in biotechnology and healthcare - Video [Last Updated On: February 19th, 2014] [Originally Added On: February 19th, 2014]
- Crippled canines get new leash on life [Last Updated On: March 27th, 2014] [Originally Added On: March 27th, 2014]
- Stem Cell Treatment for Dogs - pet insurance [Last Updated On: March 27th, 2014] [Originally Added On: March 27th, 2014]
- New patenting guidelines needed for biotechnology, experts argue [Last Updated On: April 24th, 2014] [Originally Added On: April 24th, 2014]
- New tumor-targeting agent images and treats wide variety of cancers [Last Updated On: June 24th, 2014] [Originally Added On: June 24th, 2014]
- San Diego Hosts World's Largest Biotechnology Convention - Video [Last Updated On: June 28th, 2014] [Originally Added On: June 28th, 2014]
- Shot in the arm for research on disease biology [Last Updated On: July 13th, 2014] [Originally Added On: July 13th, 2014]
- biotechnology -- Encyclopedia Britannica [Last Updated On: August 28th, 2014] [Originally Added On: August 28th, 2014]